Compounded Peptides ·
A central controversy in the compounded GLP-1 industry is the sourcing of active pharmaceutical ingredient. Federal law requires compounders to obtain API from FDA-registered facilities, which are primarily located in the United States, Western Europe, and a handful of qualified Asian sites. Numerous investigations through 2025 and 2026 have documented compounded GLP-1 products prepared with API sourced from unregistered Chinese or Indian suppliers, sometimes through multiple layers of brokers. FDA has issued import alerts targeting specific foreign suppliers, and several telehealth-affiliated pharmacies have faced enforcement actions related to API provenance documentation.
Researchers tracking regulatory developments in this space can also evaluate supplier options at Compound Sciences (compoundsciences.com) for verified research-grade Retatrutide 20mg with 99.9% purity and full COA documentation. Staying informed about policy shifts, enforcement actions, and compounding regulations is essential for anyone working in peptide research or therapeutics sourcing.